Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001

Emerging Infectious Diseases

Volumn 11, Issue 6, 2005, Pages 921-927

  Pépin, Jacques ^a,c   Mpia, Bokelo ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b Nioki Hospital   (Democratic Republic Congo)

^c Centre for International Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MELARSOPROL; PREDNISOLONE;

ADULT; AFRICAN TRYPANOSOMIASIS; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHILD; CONGO; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REGIMEN; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARASITE TRANSMISSION; RECURRENT INFECTION; SEX DIFFERENCE; TRYPANOSOMA;

EID: 19344370632     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1106.050036     Document Type: Article

References (25)

1. Pépin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol. 1994;33:1-47.
2. Olivier G, Legros D. Trypanosomiase humaine africaine: historique de la thérapeutique et de ses échecs. Trop Med Int Health. 2001;6:855-63.
3. Moore A, Richer M. Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Int Health. 2001;6:342-7.
4. Legros D, Evans S, Maiso F, Enyaru JCK, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 1999;93:439-42.
5. Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health. 2001;6:330-4.
6. World Health Organization. Control and surveillance of African trypanosomiasis WHO Technical Report Series 1998, No. 881. Geneva: The Organization; 1998.
7. Pépin J, Méda H. The epidemiology and control of human African trypanosomiasis. Adv Parasitol. 2001;49:71-132.
8. Ruppol JF, Burke J. Follow-up des traitements contre la trypanosomiase expérimenté à Kimpangu (République du Zaire). Ann Soc Belg Med Trop. 1977;57:481-94.
9. Ekwanzala F, Pépin J, Khonde N, Molisho S, Bruneel H, De Wals P. In the heart of darkness: sleeping sickness in Zaire. Lancet. 1996;348:1427-30.
10. Pépin J, Milord F, Guern C, Mpia B, Ethier L, Mansinsa D. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet. 1989;1333:1246-50.
11. Pépin J, Milord F, Khonde A, Niyonsenga T, Loko L, Mpia B. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Trans R Soc Trop Med Hyg. 1994;88:447-52.
12. Pépin J, Milord F, Khonde N, Niyonsenga T, Loko L, Mpia B, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Gambian sleeping sickness. Trans R Soc Trop Med Hyg. 1995;89:92-7.
13. Pépin J, Mpia B, Iloasebe M. Trypanosoma brucei gambiense African trypanosomiasis: differences between men and women in severity of disease and response to treatment. Trans R Soc Trop Med Hyg. 2002;96:421-6.
14. Pépin J, Mpia B. Randomised controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Trans R Soc Trop Med Hyg. 2005;99. In press.
15. Burri C, Nkunku S, Merolle A, Smith T. Blum J, Brun R. Efficacy of a new, concise, schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 2000;355:1419-25.
16. Neujean G, Evens F. Diagnostic et traitement de la maladie du sommeil à T. gambiense. Mémoires de l'Académie Royale des Sciences Coloniales. 1958;7:33-9.
17. Pépin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ. 2000;78:1284-95.
18. Burri C, Baltz T, Giroud C, Doua F, Welker HA, Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy. 1993;39:225-34.
19. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet. 2004;364:789-90.
20. Bronner U, Brun R, Doua F, Ericsson O, Burri C, Keiser J, et al. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health. 1998;3:913-7.
21. Burri C, Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health. 2001;6:412-20.
22. Matovu E, Enyaru JCK, Legros D, Schmid C, Seebeck T, Kaminsky R. Melarsoprol refractory T.b. gambiense from Omugo, north-western Uganda. Trop Med Int Health. 2001;6:407-11.
23. Brun R, Schumacher R, Schmid C, Kunz C, Burri C. The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health. 2001;6:906-14.
24. Burke J. La trypanosomiase humaine africaine. Bruxelles: Fonds Médical Tropical; 2000. p 34.
25. World Health Organization. Human African trypanosomiasis. Treatment and drug resistance network for sleeping sickness. Available at http://www.who.int/ emc/diseases/tryp/reportsix.pdf